Best of ASCO - 2014 Annual Meeting



Bladder Cancer

Genitourinary (Nonprostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.

Jeffrey S. Ross


A novel, robust multiplex urine-based immunoassay for bladder cancer detection.

Hideki Furuya


A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).

Matt D. Galsky


A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles


A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.

Daniel E. Castellano


A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.

Jianjun Gao


A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).

Nobuaki Matsubara


Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).

Petros Grivas


Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

Arjun Vasant Balar


Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Jean H. Hoffman-Censits


ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Petros Grivas


Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations.

Gregory M. Mayhew


BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

Josep Tabernero


Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).

Srikala S. Sridhar


Cell free (cf) DNA as a tumor marker in transitional cell cancer (TCC): Monitoring response to checkpoint inhibitor (CPI) therapy.

Nicholas J. Vogelzang


Cell free (cf)DNA as a tumor marker in transitional cell carcinoma (TCC).

Mohamed Azab


Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).

Rosa Nadal


Clinical validation of an ultra-deep next generation DNA sequencing approach for the detection of bladder cancer in the urine.

Jason Ablat


Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.

Mamta Parikh


Comprehensive genomic characterization of urothelial carcinomas.

Amin Nassar


Conservative management following clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: Contemporary outcomes of a multi-institutional prospective cohort study.

Patrick M Mazza


Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC).

Vadim S. Koshkin


Correlation of CD8 lymphocytes in tumors and nonsynonymous mutational load with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

Boya Deng


Determinants of guideline-based treatment in patients with cT1 bladder cancer.

Ashwin Balakrishnan


Differential expression of SRSF2 contribute to the splicing changes related to micropapillary variant histology in nonmuscle-invasive bladder cancer (NMIBC).

Adria Closa


Does neoadjuvant chemotherapy affect postoperative complication rates in elderly patients treated with radical cystectomy for bladder cancer?

Nozomi Hayakawa


Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).

Chelsea K. Osterman


Endogenous DNA damage in peripheral blood lymphocytes (PBLs) in patients with metastatic urothelial carcinoma (MUC).

Patrik Palacka


EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.

Jonathan E. Rosenberg


FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

Joaquim Bellmunt


First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

Arlene O. Siefker-Radtke


First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).

Xiao X. Wei


Identification of gene expression determinants of radiosensitivity in bladder cancer (BC) cell lines.

Jasmine Pettiford


Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).

Tian Zhang


IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Matt D. Galsky


Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder.

Sarmad Sadeghi


Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.

Amin Nassar


Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).

Kristen A Batich


Neoadjuvant chemotherapy (NAC) with dose-dense gemcitabine/cisplatin (DDGC) in localized muscle-invasive bladder cancer (MIBC).

George Tsironis


Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.

Magda Zajac


Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.

Peter H. O'Donnell


Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC).

Ariel Ann Nelson


PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

Andrea Necchi


Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.

Thomas Powles


Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

Yves Fradet


Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.

Arjun Vasant Balar


Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.

Alejo Rodriguez Vida


Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).

Jacob Adashek


Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

Xinan Sheng


Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.

Andrea Necchi


Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.

Robert John Corona


Prognostic value of genomic alterations of DNA repair genes in advanced bladder cancer (ABC).

Ming Yin


Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study.

Carlo Cattrini


Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.

Ronald De Wit


Real life outcomes of metastatic urothelial carcinoma (mUC) patients treated post first line platinum based systemic therapy: A single centre experience.

Jamila Jama Almi Rir Omar


Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.

Marco Bandini


Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

Markus Joerger


Small cell carcinoma of the urinary bladder, a single institution experience.

Gurleen Pasricha


SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US.

Gurjyot K. Doshi


SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

Simon J. Crabb


Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy.

Neda Hashemi-Sadraei


The impact of BMI on post-operative survival in bladder cancer patients.

Gray Jodon


The preliminary study for safety of acrinol, as a novel dye, which can be used to visualize cancer nuclei of bladder urothelial carcinoma, for probe-based confocal laser endomicroscopy.

Yoshio Naya


Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).

Diogo Assed Bastos


Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Jacqueline Vuky


Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

Jonathan E. Rosenberg


Upper tract urothelial carcinoma is non-basal and T-cell depleted.

Panagiotis J. Vlachostergios